Defining comprehensive models of care for NAFLD

[1]  Q. Anstee,et al.  Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease , 2021, Frontline Gastroenterology.

[2]  A. Sanyal,et al.  Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study , 2020, The Patient - Patient-Centered Outcomes Research.

[3]  V. Wong,et al.  A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients , 2020, The American journal of gastroenterology.

[4]  K. Cusi,et al.  Latin American Association for the Study of the Liver (ALEH) Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. , 2020, Annals of hepatology.

[5]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[6]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[7]  K. Trees,et al.  Providing Care for Fatty Liver Disease Patients , 2020, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[8]  H. Hagström,et al.  A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis , 2020, European journal of gastroenterology & hepatology.

[9]  D. Dieterich,et al.  Screening for Non-Alcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the U.S. is Cost Effective: A Comprehensive Cost-Utility Analysis. , 2020, Gastroenterology.

[10]  M. Moura-Ramos,et al.  Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance? , 2020, BMC Public Health.

[11]  R. Loomba,et al.  Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH , 2020, Clinical and molecular hepatology.

[12]  B. Jönsson,et al.  Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study , 2020, JHEP reports : innovation in hepatology.

[13]  A. Andreasson,et al.  Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. , 2020, Journal of hepatology.

[14]  V. Wong,et al.  Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. , 2020, Journal of gastrointestinal and liver diseases : JGLD.

[15]  U. Beuers,et al.  Non-Alcoholic Fatty Liver Disease: A Multidisciplinary Approach Towards A Cardiometabolic Liver Disease. , 2020, European journal of endocrinology.

[16]  R. Hultcrantz,et al.  Healthcare Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease are Nearly Twice Those of Matched Controls. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  P. Bossuyt,et al.  Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. , 2020, Journal of hepatology.

[18]  B. Hanratty,et al.  Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies , 2020, PLoS medicine.

[19]  G. Kaplan,et al.  Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. , 2020, CMAJ open.

[20]  S. Asch,et al.  Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease , 2020, Hepatology.

[21]  J. Schattenberg,et al.  Metabolic inflammation - a role for hepatic inflammatory pathways as driver of comorbidities in non-alcoholic fatty liver disease (NAFLD)? , 2020, Gastroenterology.

[22]  B. Neuschwander‐Tetri.  Therapeutic landscape for NAFLD in 2020. , 2020, Gastroenterology.

[23]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[24]  L. Castéra.  Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[25]  G. Berná,et al.  The role of nutrition in non‐alcoholic fatty liver disease: Pathophysiology and management , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[26]  A. Sanyal,et al.  Current management of non‐alcoholic steatohepatitis , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[27]  E. Tsochatzis,et al.  Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach , 2020, Canadian journal of gastroenterology & hepatology.

[28]  F. Tacke,et al.  A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. , 2020, Journal of hepatology.

[29]  F. Violi,et al.  Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[31]  Robert P. Myers,et al.  Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials , 2019, Hepatology.

[32]  K. Cusi,et al.  Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes , 2019, Diabetes Care.

[33]  N. Luhmann,et al.  We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade , 2019, Journal of internal medicine.

[34]  P. Galle,et al.  Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  A. Sanyal,et al.  Non-alcoholic fatty liver disease in lean individuals , 2019, JHEP reports.

[36]  K. Gurusamy,et al.  Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study , 2019, Hepatology.

[37]  L. Longworth,et al.  Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[38]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[39]  J. Hodson,et al.  Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study , 2019, Journal of hepatology.

[40]  W. Rosenberg,et al.  Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease , 2019, BMC Gastroenterology.

[41]  I. Guha,et al.  Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community , 2019, Frontline Gastroenterology.

[42]  P. Donnan,et al.  Intelligent Liver Function Testing (iLFT): A trial of automated diagnosis and staging of liver disease in Primary Care. , 2019, Journal of hepatology.

[43]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[44]  R. Holman,et al.  A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health , 2019, Frontline Gastroenterology.

[45]  Rohit Loomba,et al.  Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[46]  G. Su,et al.  Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both? , 2019, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[47]  I. Onakpoya,et al.  Better health and wellbeing for billion more people: integrating non-communicable diseases in primary care , 2019, BMJ.

[48]  A. Booth,et al.  Common risk factors for major noncommunicable disease, a systematic overview of reviews and commentary: the implied potential for targeted risk reduction , 2019, Therapeutic advances in chronic disease.

[49]  R. Hultcrantz,et al.  Cardiovascular risk factors in non‐alcoholic fatty liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[50]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[51]  B. Hanratty,et al.  GPs' experiences and perceptions of early detection of liver disease: a qualitative study in primary care. , 2018, The British journal of general practice : the journal of the Royal College of General Practitioners.

[52]  A. Sanyal.  Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing? , 2018, BMC Medicine.

[53]  N. Sattar,et al.  Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease , 2018, BMC Medicine.

[54]  N. Terrault,et al.  A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over! , 2018, Journal of hepatology.

[55]  E. Tsochatzis,et al.  Non-alcoholic fatty liver disease and the interface between primary and secondary care. , 2018, The lancet. Gastroenterology & hepatology.

[56]  D. Theisen,et al.  Physical activity promotion in primary care: a Utopian quest? , 2018, Health promotion international.

[57]  D. Haggstrom,et al.  Information technologies that facilitate care coordination: provider and patient perspectives. , 2018, Translational behavioral medicine.

[58]  G. Bedogni,et al.  Global epidemiology of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: What we need in the future , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[59]  L. Castéra.  Diagnosis of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: Non‐invasive tests are enough , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[60]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[61]  V. Wong,et al.  Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment , 2018, Journal of gastroenterology and hepatology.

[62]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[63]  R. Hultcrantz,et al.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.

[64]  M. Ekstedt,et al.  Natural History of NAFLD/NASH , 2017, Current Hepatology Reports.

[65]  R. Hultcrantz,et al.  Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[66]  Mohamed H. Ahmed,et al.  Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services , 2017, Cardiovascular endocrinology.

[67]  T. Card,et al.  Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study , 2017, BMJ Open.

[68]  P. Newsome,et al.  The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016 , 2017, Digestive Diseases.

[69]  Herbert Tilg,et al.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.

[70]  V. Ratziu.  Non‐pharmacological interventions in non‐alcoholic fatty liver disease patients , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[71]  T. Hoffmann,et al.  Telehealth methods to deliver dietary interventions in adults with chronic disease: a systematic review and meta-analysis. , 2016, The American journal of clinical nutrition.

[72]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[73]  M. Allison,et al.  Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis , 2016, The American Journal of Gastroenterology.

[74]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[75]  L. Adams,et al.  International Journal of Molecular Sciences the Natural Course of Non-alcoholic Fatty Liver Disease , 2022 .

[76]  M. Trenell,et al.  Targeting Lifestyle Behavior Change in Adults with NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise Literature , 2016, Current Gastroenterology Reports.

[77]  L. Henry,et al.  Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease , 2015, PharmacoEconomics.

[78]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[79]  Angela Coulter,et al.  Patient Experience and Satisfaction with Inpatient Service: Development of Short Form Survey Instrument Measuring the Core Aspect of Inpatient Experience , 2015, PloS one.

[80]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[81]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[82]  J. Jónasson,et al.  Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease , 2014, BMC Gastroenterology.

[83]  R. Busse,et al.  Disease management programs for type 2 diabetes in Germany: a systematic literature review evaluating effectiveness. , 2014, Deutsches Arzteblatt international.

[84]  Robert F Kushner,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[85]  Q. Anstee,et al.  Non-alcoholic fatty liver disease: a practical approach to treatment , 2014, Frontline Gastroenterology.

[86]  K. Bambha,et al.  Identifying Practice Gaps to Optimize Medical Care for Patients with Nonalcoholic Fatty Liver Disease , 2013, Digestive Diseases and Sciences.

[87]  Rohit Kohli,et al.  A Multidisciplinary Clinical Program Is Effective in Stabilizing BMI and Reducing Transaminase Levels in Pediatric Patients With NAFLD , 2013, Journal of pediatric gastroenterology and nutrition.

[88]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[89]  Hocheol Shin,et al.  Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in korean men: 5‐year prospective cohort study , 2013, Hepatology.

[90]  Tony Blakely,et al.  Inequalities in non-communicable diseases and effective responses , 2013, The Lancet.

[91]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[92]  M. Dimatteo,et al.  The challenge of patient adherence , 2005, Therapeutics and clinical risk management.

[93]  L. Mascitelli,et al.  Diagnosis of nonalcoholic fatty liver disease. , 2003, JAMA.

[94]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[95]  Providing Care for Fatty Liver Disease Patients: Primary Care Nurse Practitioners' Knowledge, Actions, and Preparedness. , 2020, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[96]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[97]  M. Armstrong,et al.  Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. , 2014, QJM : monthly journal of the Association of Physicians.

[98]  Michael D. Jensen,et al.  Reprint: 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.